| Literature DB >> 23324222 |
Maysoon Jabir1, Imad Abdul-Salam, Dhikra M Suheil, Wafa Al-Hilli, Sana Abul-Hassan, Amal Al-Zuheiri, Rasha Al-Ba'aj, Abeer Dekan, Ozge Tunçalp, Joao Paulo Souza.
Abstract
BACKGROUND: The maternal near-miss concept has been developed as an instrument for assisting health systems to evaluate and improve their quality of care. Our study aimed at studying the characteristics and quality of care provided to women with severe complications in Baghdad through the use of the World Health Organization (WHO) near-miss approach for maternal health.Entities:
Mesh:
Year: 2013 PMID: 23324222 PMCID: PMC3558361 DOI: 10.1186/1471-2393-13-11
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Maternal near-miss terminology and indicators[8,9]
| A woman who nearly died but survived a complication that occurred during pregnancy, childbirth or within 42 days of termination of pregnancy. | |
| Death of a woman while pregnant or within 42 days of termination of pregnancy or its management, but not from accidental or incidental causes. | |
| The birth of an offspring, which breathes or shows evidence of life. | |
| A life-threatening condition (i.e. organ dysfunction), including all maternal deaths and maternal near-miss cases. | |
| All women who either qualified as having maternal near miss or who died. It is the sum of maternal near miss and maternal deaths. | |
| The number of maternal near miss cases per 1,000 live births. | |
| The number of women with life threatening conditions per 1,000 live births. This indication gives an estimation of the amount of care and resources that would be needed in an area or facility. | |
| The ratio between maternal near-miss cases and maternal deaths. Higher ratios indicate better care. | |
| The number of maternal deaths divided by the number of women with life threatening conditions, expressed as a percentage. The higher the index the more women with life-threatening conditions die (low quality of care), whereas the lower the index the fewer women with life-threatening conditions die (better quality of care). | |
| (e.g. perinatal mortality, neonatal mortality or stillbirth rates) in the context of maternal miss could be useful to complement the quality of care evaluation. | |
| | |
| The following indicators are used to explore the access to the facility in terms of functioning referral systems. | · |
| · | |
| · Proportion of SMO12 cases coming from other facilities | |
| · | |
| | |
| The following indicators are used to explore access to quality care in the facility: | · |
| · | |
| · | |
| · | |
| · | |
| | |
| The following indicators are used to assess the coverage of selected evidence-based interventions used for prevention and treatment of the main causes of maternal deaths. | · |
| · | |
| · | |
| · | |
| · | |
| · |
Morbidity conditions leading to inclusion in a sample of women with potentially life-threatening conditions and severe maternal outcomes
| 212 | 100.00% | |
| 174 | 82.08% | |
| Severe postpartum hemorrhage | 84 | 39.62% |
| Severe Preeclampsia | 4 | 1.89% |
| Eclampsia | 43 | 20.28% |
| Sepsis or severe systemic infection | 10 | 4.72% |
| Ruptured uterus | 29 | 13.68% |
| Other complications associated with severe maternal outcome | 22 | 10.38% |
| 181 | 85.38% | |
| Use of blood products | 118 | 55.66% |
| Interventional radiology (uterine artery embolization) | 2 | 0.94% |
| Laparotomy | 85 | 40.09% |
| Admission to Intensive Care Unit | 73 | 34.43% |
| 129 | 100.00% | |
| Cardiovascular dysfunction | 72 | 55.81% |
| Respiratory dysfunction | 30 | 23.26% |
| Renal dysfunction | 6 | 4.65% |
| Coagulation/hematologic dysfunction | 30 | 23.26% |
| Hepatic dysfunction | 5 | 3.88% |
| Neurologic dysfunction | 23 | 17.83% |
| Uterine dysfunction/hysterectomy | 69 | 53.49% |
| Multiple organ dysfunction | 64 | 49.61% |
| 16 | 100.00% | |
| Cardiovascular dysfunction | 7 | 43.75% |
| Respiratory dysfunction | 8 | 50.00% |
| Renal dysfunction | 4 | 25.00% |
| Coagulation/hematologic dysfunction | 3 | 18.75% |
| Hepatic dysfunction | 0 | 0.00% |
| Neurologic dysfunction | 4 | 25.00% |
| Uterine dysfunction/hysterectomy | 6 | 37.50% |
| Unspecified organ dysfunction | 1 | 6.25% |
| Multiple organ dysfunction | 9 | 56.25% |
Underlying causes of potentially life-threatening conditions and severe maternal outcomes
| | N= | 212 | N= | 129 | N= | 16 |
| | n | % | n | % | n | % |
| | | | | | | |
| Pregnancy with abortive outcome | 44 | 20.75% | 6 | 4.65% | 1 | 6.25% |
| Obstetric Hemorrhage | 99 | 46.70% | 85 | 65.89% | 7 | 43.75% |
| Hypertensive disorders | 49 | 23.11% | 27 | 20.93% | 4 | 25.00% |
| Pregnancy-related infection | 9 | 4.25% | 4 | 3.10% | 1 | 6.25% |
| Other obstetric disease or complication | 28 | 13.21% | 22 | 17.05% | 1 | 6.25% |
| Medical/Surgical/Mental disease or complication | 38 | 17.92% | 26 | 20.16% | 5 | 31.25% |
| Unanticipated complications of management | 14 | 6.60% | 11 | 8.53% | 1 | 6.25% |
| Coincidental conditions | 10 | 4.72% | 8 | 6.20% | 2 | 12.50% |
| Unknown | 4 | 1.89% | 3 | 2.33% | 1 | 6.25% |
| | | | | | | |
| Anemia | 96 | 45.28% | 71 | 55.04% | 8 | 50.00% |
| HIV infection | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
| Previous caesarean section | 74 | 34.91% | 58 | 44.96% | 7 | 43.75% |
| Prolonged / obstructed labor | 28 | 13.21% | 21 | 16.28% | 3 | 18.75% |
End of pregnancy and pregnancy outcomes in our study population
| | N= | 212 | N= | 129. | N= | 16 |
| | n | % | n | % | n | % |
| | | | | | | |
| Vaginal delivery | 46 | 21.70% | 37 | 28.68% | 3 | 18.75% |
| Caesarean Section | 107 | 50.47% | 78 | 60.47% | 11 | 68.75% |
| Complete abortion | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
| Curettage / vacuum aspiration | 7 | 3.30% | 5 | 3.88% | 0 | 0.00% |
| Medical methods for uterine evacuation | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
| Laparotomy for ectopic pregnancy | 39 | 18.40% | 1 | 0.78% | 1 | 6.25% |
| Other | 4 | 1.89% | 2 | 1.55% | 0 | 0.00% |
| Unknown | 2 | 0.94% | 1 | 0.78% | 0 | 0.00% |
| Women still pregnant at hospital discharge or death | 7 | 3.30% | 5 | 3.88% | 1 | 6.25% |
| n/a | 69.93% | n/a | 67.83% | n/a | 78.57% | |
| 57 | 37.25% | 42 | 36.52% | 8 | 57.14% | |
| 32 | 20.92% | 23 | 20.00% | 6 | 42.86% | |
| 65 | 42.48% | 50 | 43.48% | 7 | 50.00% | |
*Caesarean deliveries divided by all deliveries / **fetal deaths + intra-hospital early neonatal mortality.
Severe maternal outcomes and near miss indicators
| 25,472 | |
|---|---|
| 145 | |
| Maternal Deaths (n) | 16 |
| Maternal near miss cases (n) | 129 |
| | |
| Severe Maternal Outcome ratio (per 1000 live births) | 5.69 |
| Maternal near miss incidence ratio (per 1000 live births) | 5.06 |
| Maternal near miss mortality ratio | 9:1 |
| Mortality index | 11.03% |
| | |
| SMO cases presenting the organ dysfunction or maternal death within 12 hours of hospital stay (SMO12) (n) | 127 |
| Proportion of SMO12 cases among all SMO cases | 87.59% |
| Proportion of SMO12 cases coming from other health facilities | 34.65% |
| SMO12 mortality index | 11.02% |
| | |
| Intra-hospital SMO cases (n) | 18 |
| Intra-hospital SMO rate (per 1000 live births) | 0.71 |
| Intra-Hospital mortality index | 11.11% |
Intensive care use in our study population
| ICU admission rate | 0.28% |
| ICU admission rate among women with SMO | 37.24% |
| SMO rate among women admitted to ICU | 73.97% |
| Proportion of maternal deaths occurred without ICU admission | 50.00% |
Process outcome indicators related with specific conditions among women with severe maternal outcomes (maternal near miss and maternal deaths)
| | | |
| Target population: women giving birth in health facilities | 132 | 100.00% |
| Oxytocin | 114 | 86.36% |
| Any uterotonic (including oxytocin) | 115 | 87.12% |
| | | |
| Target population: women with severe PPH | 84 | 100.00% |
| Oxytocin | 57 | 67.86% |
| Ergometrine | 52 | 61.90% |
| Misoprostol | 35 | 41.67% |
| Other uterotonics | 3. | 3.57% |
| Any of the above uterotonics | 57 | 67.86% |
| Tranexamic acid | 6 | 7.14% |
| Removal of retained products | 16 | 19.05% |
| Balloon or condom tamponade | 1. | 1.19% |
| Artery ligation | 4 | 4.76% |
| Hysterectomy | 50 | 59.52% |
| Abdominal packing | 4 | 4.76% |
| Proportion of cases with SMO | 80 | 95.24% |
| Mortality | 6. | 7.14% |
| | | |
| Target population: women with eclampsia | 43 | 100.00% |
| Magnesium sulfate | 29 | 67.44% |
| Other anticonvulsant | 22 | 51.16% |
| Any anticonvulsant | 40 | 93.02% |
| Proportion of cases with SMO | 26 | 60.47% |
| Mortality | 4 | 9.30% |
| | | |
| Target population: women undergoing caesarean section | 107 | 100.00% |
| Prophylactic antibiotic during caesarean section | 65 | 60.75% |
| | | |
| Target population: women with sepsis | 10 | 100.00% |
| Parenteral therapeutic antibiotics | 10 | 100.00% |
| Proportion of cases with SMO | 6 | 60.00% |
| Mortality | 2 | 20.00% |
| | | |
| Target population: women with ruptured uterus | 29 | 100.00% |
| Laparotomy | 28 | 96.55% |
| Laparotomy after 3 hours of hospital stay | 5 | 17.24% |
| Proportion of cases with SMO | 24 | 82.76% |
| Mortality | 3 | 10.34% |
| | | |
| Target population: women having a preterm delivery after 3 hours of hospital stay | 18 | 100.00% |
| Corticosteroids for fetal lung maturation | 10 | 55.56% |